Camizestrant

AUG 19, 2026 · PHASE 3 TRIAL

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

ClinicalTrials.gov

This is an active Phase 3 trial registration with no reported results; the study design and primary endpoint are specified but outcome data are not yet available.

AUG 10, 2026 · PHASE 3 TRIAL

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

ClinicalTrials.gov

This is an active Phase 3 trial registration with no results posted; the study is ongoing and has not yet reported efficacy or safety outcomes.

AUG 10, 2026 · PHASE 3 TRIAL

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

ClinicalTrials.gov

Phase IIIb registration record with no results posted; describes planned enrollment and primary outcome measure only, without efficacy or safety data.

AUG 7, 2026 · PHASE 2 TRIAL

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

ClinicalTrials.gov

This is a recruiting Phase 2 study with no results posted; it describes a planned safety and tolerability evaluation in a small population with an estimated 24 participants.